PCSK9 and metabolic syndrome: After adjusting for changes in TC levels, numbers of circulating EPCs, and history of metabolic syndrome, use of cilostazol remained independently associated with changes in the plasma PCSK9 levels [beta = 0.20 (95% confidence interval = 0.02-0.48), P = 0.04] (Table 5).